Intra-Cellular Therapies Inc. (ITCI) Given Consensus Recommendation of “Buy” by Analysts
Intra-Cellular Therapies Inc. (NASDAQ:ITCI) has received a consensus rating of “Buy” from the twelve research firms that are presently covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a sell recommendation, two have given a hold recommendation and eight have issued a buy recommendation on the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $29.00.
A number of equities analysts have recently weighed in on the company. Piper Jaffray Companies set a $10.00 price target on Intra-Cellular Therapies and gave the stock a “hold” rating in a report on Thursday, August 10th. Cantor Fitzgerald reissued a “buy” rating on shares of Intra-Cellular Therapies in a report on Wednesday, August 9th. BidaskClub cut Intra-Cellular Therapies from a “hold” rating to a “sell” rating in a report on Saturday, August 5th. Zacks Investment Research raised Intra-Cellular Therapies from a “hold” rating to a “buy” rating and set a $12.00 price target for the company in a report on Tuesday, August 15th. Finally, ValuEngine raised Intra-Cellular Therapies from a “strong sell” rating to a “sell” rating in a report on Friday, August 18th.
COPYRIGHT VIOLATION WARNING: This story was first reported by Watch List News and is the property of of Watch List News. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this story can be viewed at https://www.watchlistnews.com/intra-cellular-therapies-inc-itci-given-consensus-recommendation-of-buy-by-analysts/1583610.html.
Intra-Cellular Therapies (NASDAQ:ITCI) traded up 0.21% on Friday, reaching $19.29. The company had a trading volume of 569,858 shares. Intra-Cellular Therapies has a 52-week low of $7.85 and a 52-week high of $44.19. The company’s market capitalization is $837.65 million. The company’s 50-day moving average is $15.29 and its 200-day moving average is $13.12.
Intra-Cellular Therapies (NASDAQ:ITCI) last issued its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.74) by $0.33. Intra-Cellular Therapies had a negative return on equity of 27.92% and a negative net margin of 32,834.94%. The firm had revenue of $0.11 million during the quarter, compared to analysts’ expectations of $0.03 million. During the same period in the previous year, the firm posted ($0.71) earnings per share. Intra-Cellular Therapies’s revenue was down 52.2% on a year-over-year basis. Equities analysts anticipate that Intra-Cellular Therapies will post ($2.36) EPS for the current fiscal year.
A number of institutional investors have recently added to or reduced their stakes in the stock. FMR LLC increased its stake in Intra-Cellular Therapies by 0.3% in the first quarter. FMR LLC now owns 6,511,541 shares of the biopharmaceutical company’s stock valued at $105,813,000 after purchasing an additional 21,305 shares during the last quarter. Vanguard Group Inc. increased its stake in Intra-Cellular Therapies by 7.3% in the first quarter. Vanguard Group Inc. now owns 2,741,887 shares of the biopharmaceutical company’s stock valued at $44,556,000 after purchasing an additional 186,165 shares during the last quarter. BB Biotech AG increased its stake in Intra-Cellular Therapies by 11.7% in the second quarter. BB Biotech AG now owns 2,150,000 shares of the biopharmaceutical company’s stock valued at $26,703,000 after purchasing an additional 225,000 shares during the last quarter. Wasatch Advisors Inc. increased its stake in Intra-Cellular Therapies by 65.1% in the second quarter. Wasatch Advisors Inc. now owns 1,659,513 shares of the biopharmaceutical company’s stock valued at $20,611,000 after purchasing an additional 654,400 shares during the last quarter. Finally, State Street Corp increased its stake in Intra-Cellular Therapies by 10.4% in the second quarter. State Street Corp now owns 1,004,360 shares of the biopharmaceutical company’s stock valued at $12,474,000 after purchasing an additional 94,763 shares during the last quarter. Hedge funds and other institutional investors own 71.79% of the company’s stock.
About Intra-Cellular Therapies
Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).
Receive News & Ratings for Intra-Cellular Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.